β2-上腺受体刺激关节骨炎 - - 现在是重新考虑预防和治疗的时候了
Zsuzsa Jenei-Lanzl1, Rainer H Straub2
1Dr. Rolf M. Schwiete Research Unit for Osteoarthritis, Department of Trauma Surgery and Orthopedics, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Osteoarthritis and cartilage
|June 30, 2024
概括
交感神经系统,特别是β2-上腺受体 (AR),促进骨关节炎 (OA). 向β2-AR为新型OA疗法提供了潜力.
科学领域:
- 神经内分泌学神经内分泌学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨关节炎 (OA) 的发病包括局部和系统因素,神经内分泌机制经常被忽视.
- 交感神经系统 (SNS) 在OA进展中发挥着重要作用.
- β2-上腺受体 (AR) 是SNS驱动的OA效应的关键调解者.
研究的目的:
- 在过去的二十年中,审查β2-上腺受体 (AR) 促进OA的作用.
- 突出SNS和β2-AR在受OA影响的关节组织中的参与.
- 刺激对针对β2-AR的新型治疗策略的研究,以预防和治疗OA.
主要方法:
- 在体外,体内和临床研究的文献综述.
- 对交感神经系统参与骨关节炎的研究进行分析.
- 综合与OA中的β2-上腺受体功能相关的发现.
主要成果:
- 证据证实β2-上腺受体在关节组织中介导显著的OA促进作用.
- 多项研究表明β2-AR在OA发病和进展中的作用.
- 通过β2-AR,SNS会影响OA关节的各种组成部分.
结论:
- β2-腺受体是骨关节炎发病的关键因素.
- 准β2-上腺受体为开发新的OA治疗提供了一个有希望的途径.
- 需要进一步的研究,以探索专注于OA β2-AR途径的创新治疗策略.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
685
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
685
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
702
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
702
Antihypertensive Drugs: Action of β1 Blockers
416
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
416
Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
Antihypertensive Drugs: Types of β-Blockers
635
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
635
Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700


